nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—melanoma	0.316	1	CbGaD
Paroxetine—CHRM5—skin epidermis—melanoma	0.00109	0.171	CbGeAlD
Paroxetine—HTR2A—hindlimb—melanoma	0.000509	0.0796	CbGeAlD
Paroxetine—HTR2A—appendage—melanoma	0.000436	0.0683	CbGeAlD
Paroxetine—Chills—Temozolomide—melanoma	0.000433	0.00107	CcSEcCtD
Paroxetine—Dehydration—Docetaxel—melanoma	0.000432	0.00107	CcSEcCtD
Paroxetine—Ill-defined disorder—Dactinomycin—melanoma	0.000431	0.00107	CcSEcCtD
Paroxetine—Anaemia—Dactinomycin—melanoma	0.00043	0.00106	CcSEcCtD
Paroxetine—Liver function test abnormal—Docetaxel—melanoma	0.000429	0.00106	CcSEcCtD
Paroxetine—Vomiting—Vemurafenib—melanoma	0.000427	0.00105	CcSEcCtD
Paroxetine—Alopecia—Temozolomide—melanoma	0.000427	0.00105	CcSEcCtD
Paroxetine—Dry skin—Docetaxel—melanoma	0.000426	0.00105	CcSEcCtD
Paroxetine—Chest pain—Bleomycin—melanoma	0.000424	0.00105	CcSEcCtD
Paroxetine—Myalgia—Bleomycin—melanoma	0.000424	0.00105	CcSEcCtD
Paroxetine—Orthostatic hypotension—Docetaxel—melanoma	0.000424	0.00105	CcSEcCtD
Paroxetine—Rash—Vemurafenib—melanoma	0.000423	0.00105	CcSEcCtD
Paroxetine—Mental disorder—Temozolomide—melanoma	0.000423	0.00105	CcSEcCtD
Paroxetine—Dermatitis—Vemurafenib—melanoma	0.000423	0.00104	CcSEcCtD
Paroxetine—Back pain—Carmustine—melanoma	0.000421	0.00104	CcSEcCtD
Paroxetine—Headache—Vemurafenib—melanoma	0.000421	0.00104	CcSEcCtD
Paroxetine—Erythema—Temozolomide—melanoma	0.00042	0.00104	CcSEcCtD
Paroxetine—Malnutrition—Temozolomide—melanoma	0.00042	0.00104	CcSEcCtD
Paroxetine—Breast disorder—Docetaxel—melanoma	0.00042	0.00104	CcSEcCtD
Paroxetine—Discomfort—Bleomycin—melanoma	0.000419	0.00104	CcSEcCtD
Paroxetine—Malaise—Dactinomycin—melanoma	0.000419	0.00104	CcSEcCtD
Paroxetine—Cramp muscle—Docetaxel—melanoma	0.000418	0.00103	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000418	0.00103	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000418	0.00103	CcSEcCtD
Paroxetine—Leukopenia—Dactinomycin—melanoma	0.000416	0.00103	CcSEcCtD
Paroxetine—Nasopharyngitis—Docetaxel—melanoma	0.000415	0.00103	CcSEcCtD
Paroxetine—Dysgeusia—Temozolomide—melanoma	0.000412	0.00102	CcSEcCtD
Paroxetine—Confusional state—Bleomycin—melanoma	0.00041	0.00101	CcSEcCtD
Paroxetine—Vision blurred—Carmustine—melanoma	0.00041	0.00101	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000409	0.00101	CcSEcCtD
Paroxetine—Tremor—Carmustine—melanoma	0.000408	0.00101	CcSEcCtD
Paroxetine—Oedema—Bleomycin—melanoma	0.000407	0.001	CcSEcCtD
Paroxetine—Anaphylactic shock—Bleomycin—melanoma	0.000407	0.001	CcSEcCtD
Paroxetine—Back pain—Temozolomide—melanoma	0.000407	0.001	CcSEcCtD
Paroxetine—Infection—Bleomycin—melanoma	0.000404	0.000998	CcSEcCtD
Paroxetine—Anaemia—Carmustine—melanoma	0.000402	0.000993	CcSEcCtD
Paroxetine—Dysphagia—Docetaxel—melanoma	0.000401	0.000991	CcSEcCtD
Paroxetine—Agitation—Carmustine—melanoma	0.0004	0.000988	CcSEcCtD
Paroxetine—Nausea—Vemurafenib—melanoma	0.000399	0.000985	CcSEcCtD
Paroxetine—Thrombocytopenia—Bleomycin—melanoma	0.000398	0.000984	CcSEcCtD
Paroxetine—Vision blurred—Temozolomide—melanoma	0.000396	0.000979	CcSEcCtD
Paroxetine—Myalgia—Dactinomycin—melanoma	0.000396	0.000978	CcSEcCtD
Paroxetine—Tremor—Temozolomide—melanoma	0.000394	0.000973	CcSEcCtD
Paroxetine—Discomfort—Dactinomycin—melanoma	0.000391	0.000966	CcSEcCtD
Paroxetine—Angina pectoris—Docetaxel—melanoma	0.000391	0.000966	CcSEcCtD
Paroxetine—Ill-defined disorder—Temozolomide—melanoma	0.00039	0.000964	CcSEcCtD
Paroxetine—Leukopenia—Carmustine—melanoma	0.000389	0.000962	CcSEcCtD
Paroxetine—CHRM5—eye—melanoma	0.000389	0.0609	CbGeAlD
Paroxetine—Anaemia—Temozolomide—melanoma	0.000389	0.00096	CcSEcCtD
Paroxetine—Agitation—Temozolomide—melanoma	0.000386	0.000954	CcSEcCtD
Paroxetine—Angioedema—Temozolomide—melanoma	0.000384	0.000949	CcSEcCtD
Paroxetine—Pancytopenia—Docetaxel—melanoma	0.000381	0.000941	CcSEcCtD
Paroxetine—Hypotension—Bleomycin—melanoma	0.00038	0.000939	CcSEcCtD
Paroxetine—Oedema—Dactinomycin—melanoma	0.000379	0.000937	CcSEcCtD
Paroxetine—Malaise—Temozolomide—melanoma	0.000379	0.000937	CcSEcCtD
Paroxetine—Vertigo—Temozolomide—melanoma	0.000378	0.000933	CcSEcCtD
Paroxetine—Convulsion—Carmustine—melanoma	0.000377	0.000931	CcSEcCtD
Paroxetine—Infection—Dactinomycin—melanoma	0.000377	0.000931	CcSEcCtD
Paroxetine—Leukopenia—Temozolomide—melanoma	0.000376	0.00093	CcSEcCtD
Paroxetine—Hypertension—Carmustine—melanoma	0.000376	0.000928	CcSEcCtD
Paroxetine—Palpitations—Temozolomide—melanoma	0.000372	0.000918	CcSEcCtD
Paroxetine—Thrombocytopenia—Dactinomycin—melanoma	0.000371	0.000918	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000371	0.000915	CcSEcCtD
Paroxetine—Myalgia—Carmustine—melanoma	0.00037	0.000915	CcSEcCtD
Paroxetine—Chest pain—Carmustine—melanoma	0.00037	0.000915	CcSEcCtD
Paroxetine—Anxiety—Carmustine—melanoma	0.000369	0.000912	CcSEcCtD
Paroxetine—Cough—Temozolomide—melanoma	0.000367	0.000906	CcSEcCtD
Paroxetine—Paraesthesia—Bleomycin—melanoma	0.000365	0.000902	CcSEcCtD
Paroxetine—Weight increased—Docetaxel—melanoma	0.000365	0.000902	CcSEcCtD
Paroxetine—Convulsion—Temozolomide—melanoma	0.000364	0.0009	CcSEcCtD
Paroxetine—Weight decreased—Docetaxel—melanoma	0.000363	0.000897	CcSEcCtD
Paroxetine—Hypertension—Temozolomide—melanoma	0.000363	0.000897	CcSEcCtD
Paroxetine—Dyspnoea—Bleomycin—melanoma	0.000363	0.000896	CcSEcCtD
Paroxetine—Pneumonia—Docetaxel—melanoma	0.00036	0.000889	CcSEcCtD
Paroxetine—Confusional state—Carmustine—melanoma	0.000358	0.000884	CcSEcCtD
Paroxetine—Arthralgia—Temozolomide—melanoma	0.000358	0.000884	CcSEcCtD
Paroxetine—Myalgia—Temozolomide—melanoma	0.000358	0.000884	CcSEcCtD
Paroxetine—Anxiety—Temozolomide—melanoma	0.000357	0.000881	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000355	0.000878	CcSEcCtD
Paroxetine—Oedema—Carmustine—melanoma	0.000355	0.000877	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000355	0.000876	CcSEcCtD
Paroxetine—Discomfort—Temozolomide—melanoma	0.000354	0.000874	CcSEcCtD
Paroxetine—Decreased appetite—Bleomycin—melanoma	0.000354	0.000873	CcSEcCtD
Paroxetine—Infection—Carmustine—melanoma	0.000353	0.000871	CcSEcCtD
Paroxetine—Acute coronary syndrome—Docetaxel—melanoma	0.000353	0.000871	CcSEcCtD
Paroxetine—Myocardial infarction—Docetaxel—melanoma	0.000351	0.000866	CcSEcCtD
Paroxetine—Neuropathy peripheral—Docetaxel—melanoma	0.000351	0.000866	CcSEcCtD
Paroxetine—Dry mouth—Temozolomide—melanoma	0.00035	0.000865	CcSEcCtD
Paroxetine—Jaundice—Docetaxel—melanoma	0.000349	0.000861	CcSEcCtD
Paroxetine—Stomatitis—Docetaxel—melanoma	0.000349	0.000861	CcSEcCtD
Paroxetine—Pain—Bleomycin—melanoma	0.000348	0.000859	CcSEcCtD
Paroxetine—Conjunctivitis—Docetaxel—melanoma	0.000348	0.000859	CcSEcCtD
Paroxetine—Thrombocytopenia—Carmustine—melanoma	0.000348	0.000859	CcSEcCtD
Paroxetine—Tachycardia—Carmustine—melanoma	0.000347	0.000856	CcSEcCtD
Paroxetine—Confusional state—Temozolomide—melanoma	0.000346	0.000855	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000346	0.000854	CcSEcCtD
Paroxetine—Anaphylactic shock—Temozolomide—melanoma	0.000343	0.000848	CcSEcCtD
Paroxetine—Oedema—Temozolomide—melanoma	0.000343	0.000848	CcSEcCtD
Paroxetine—Infection—Temozolomide—melanoma	0.000341	0.000842	CcSEcCtD
Paroxetine—CHRM5—skin of body—melanoma	0.000339	0.053	CbGeAlD
Paroxetine—Hepatobiliary disease—Docetaxel—melanoma	0.000338	0.000836	CcSEcCtD
Paroxetine—Epistaxis—Docetaxel—melanoma	0.000337	0.000834	CcSEcCtD
Paroxetine—Nervous system disorder—Temozolomide—melanoma	0.000337	0.000831	CcSEcCtD
Paroxetine—Thrombocytopenia—Temozolomide—melanoma	0.000336	0.00083	CcSEcCtD
Paroxetine—Feeling abnormal—Bleomycin—melanoma	0.000335	0.000828	CcSEcCtD
Paroxetine—Agranulocytosis—Docetaxel—melanoma	0.000334	0.000825	CcSEcCtD
Paroxetine—Skin disorder—Temozolomide—melanoma	0.000333	0.000823	CcSEcCtD
Paroxetine—Hypotension—Carmustine—melanoma	0.000332	0.00082	CcSEcCtD
Paroxetine—Hyperhidrosis—Temozolomide—melanoma	0.000332	0.000819	CcSEcCtD
Paroxetine—Decreased appetite—Dactinomycin—melanoma	0.00033	0.000815	CcSEcCtD
Paroxetine—Fatigue—Dactinomycin—melanoma	0.000327	0.000808	CcSEcCtD
Paroxetine—Pain—Dactinomycin—melanoma	0.000324	0.000801	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Carmustine—melanoma	0.000324	0.000799	CcSEcCtD
Paroxetine—Urticaria—Bleomycin—melanoma	0.000323	0.000798	CcSEcCtD
Paroxetine—Haemoglobin—Docetaxel—melanoma	0.000323	0.000797	CcSEcCtD
Paroxetine—Rhinitis—Docetaxel—melanoma	0.000322	0.000795	CcSEcCtD
Paroxetine—Body temperature increased—Bleomycin—melanoma	0.000322	0.000794	CcSEcCtD
Paroxetine—Haemorrhage—Docetaxel—melanoma	0.000321	0.000793	CcSEcCtD
Paroxetine—Hepatitis—Docetaxel—melanoma	0.000321	0.000793	CcSEcCtD
Paroxetine—Insomnia—Carmustine—melanoma	0.000321	0.000793	CcSEcCtD
Paroxetine—Hypoaesthesia—Docetaxel—melanoma	0.00032	0.000789	CcSEcCtD
Paroxetine—Paraesthesia—Carmustine—melanoma	0.000319	0.000788	CcSEcCtD
Paroxetine—Pharyngitis—Docetaxel—melanoma	0.000319	0.000787	CcSEcCtD
Paroxetine—Dyspnoea—Carmustine—melanoma	0.000317	0.000782	CcSEcCtD
Paroxetine—Oedema peripheral—Docetaxel—melanoma	0.000316	0.000782	CcSEcCtD
Paroxetine—Somnolence—Carmustine—melanoma	0.000316	0.00078	CcSEcCtD
Paroxetine—Connective tissue disorder—Docetaxel—melanoma	0.000316	0.00078	CcSEcCtD
Paroxetine—Feeling abnormal—Dactinomycin—melanoma	0.000313	0.000772	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000313	0.000772	CcSEcCtD
Paroxetine—Insomnia—Temozolomide—melanoma	0.00031	0.000767	CcSEcCtD
Paroxetine—Gastrointestinal pain—Dactinomycin—melanoma	0.00031	0.000766	CcSEcCtD
Paroxetine—Visual impairment—Docetaxel—melanoma	0.00031	0.000765	CcSEcCtD
Paroxetine—Decreased appetite—Carmustine—melanoma	0.000309	0.000762	CcSEcCtD
Paroxetine—Paraesthesia—Temozolomide—melanoma	0.000308	0.000761	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Carmustine—melanoma	0.000307	0.000757	CcSEcCtD
Paroxetine—Dyspnoea—Temozolomide—melanoma	0.000306	0.000756	CcSEcCtD
Paroxetine—Somnolence—Temozolomide—melanoma	0.000305	0.000753	CcSEcCtD
Paroxetine—Erythema multiforme—Docetaxel—melanoma	0.000304	0.00075	CcSEcCtD
Paroxetine—Pain—Carmustine—melanoma	0.000304	0.00075	CcSEcCtD
Paroxetine—Constipation—Carmustine—melanoma	0.000304	0.00075	CcSEcCtD
Paroxetine—Dyspepsia—Temozolomide—melanoma	0.000302	0.000746	CcSEcCtD
Paroxetine—TACR1—head—melanoma	0.000301	0.0471	CbGeAlD
Paroxetine—Eye disorder—Docetaxel—melanoma	0.0003	0.000741	CcSEcCtD
Paroxetine—Abdominal pain—Dactinomycin—melanoma	0.0003	0.000741	CcSEcCtD
Paroxetine—Body temperature increased—Dactinomycin—melanoma	0.0003	0.000741	CcSEcCtD
Paroxetine—Hypersensitivity—Bleomycin—melanoma	0.0003	0.00074	CcSEcCtD
Paroxetine—Decreased appetite—Temozolomide—melanoma	0.000298	0.000737	CcSEcCtD
Paroxetine—Cardiac disorder—Docetaxel—melanoma	0.000298	0.000736	CcSEcCtD
Paroxetine—Flushing—Docetaxel—melanoma	0.000298	0.000736	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Temozolomide—melanoma	0.000296	0.000732	CcSEcCtD
Paroxetine—Fatigue—Temozolomide—melanoma	0.000296	0.000731	CcSEcCtD
Paroxetine—Pain—Temozolomide—melanoma	0.000293	0.000725	CcSEcCtD
Paroxetine—Constipation—Temozolomide—melanoma	0.000293	0.000725	CcSEcCtD
Paroxetine—Feeling abnormal—Carmustine—melanoma	0.000293	0.000723	CcSEcCtD
Paroxetine—Asthenia—Bleomycin—melanoma	0.000292	0.000721	CcSEcCtD
Paroxetine—Angiopathy—Docetaxel—melanoma	0.000291	0.00072	CcSEcCtD
Paroxetine—Gastrointestinal pain—Carmustine—melanoma	0.00029	0.000717	CcSEcCtD
Paroxetine—Immune system disorder—Docetaxel—melanoma	0.00029	0.000717	CcSEcCtD
Paroxetine—Mediastinal disorder—Docetaxel—melanoma	0.000289	0.000715	CcSEcCtD
Paroxetine—Chills—Docetaxel—melanoma	0.000288	0.000712	CcSEcCtD
Paroxetine—Pruritus—Bleomycin—melanoma	0.000288	0.000711	CcSEcCtD
Paroxetine—Arrhythmia—Docetaxel—melanoma	0.000287	0.000709	CcSEcCtD
Paroxetine—Alopecia—Docetaxel—melanoma	0.000284	0.000701	CcSEcCtD
Paroxetine—CHRM4—head—melanoma	0.000283	0.0442	CbGeAlD
Paroxetine—Feeling abnormal—Temozolomide—melanoma	0.000283	0.000698	CcSEcCtD
Paroxetine—Mental disorder—Docetaxel—melanoma	0.000281	0.000695	CcSEcCtD
Paroxetine—Body temperature increased—Carmustine—melanoma	0.000281	0.000693	CcSEcCtD
Paroxetine—Abdominal pain—Carmustine—melanoma	0.000281	0.000693	CcSEcCtD
Paroxetine—Gastrointestinal pain—Temozolomide—melanoma	0.000281	0.000693	CcSEcCtD
Paroxetine—Erythema—Docetaxel—melanoma	0.00028	0.000691	CcSEcCtD
Paroxetine—Malnutrition—Docetaxel—melanoma	0.00028	0.000691	CcSEcCtD
Paroxetine—Hypersensitivity—Dactinomycin—melanoma	0.00028	0.00069	CcSEcCtD
Paroxetine—Dysgeusia—Docetaxel—melanoma	0.000274	0.000676	CcSEcCtD
Paroxetine—Urticaria—Temozolomide—melanoma	0.000273	0.000673	CcSEcCtD
Paroxetine—Asthenia—Dactinomycin—melanoma	0.000272	0.000672	CcSEcCtD
Paroxetine—Body temperature increased—Temozolomide—melanoma	0.000271	0.00067	CcSEcCtD
Paroxetine—Abdominal pain—Temozolomide—melanoma	0.000271	0.00067	CcSEcCtD
Paroxetine—Back pain—Docetaxel—melanoma	0.00027	0.000668	CcSEcCtD
Paroxetine—Muscle spasms—Docetaxel—melanoma	0.000269	0.000664	CcSEcCtD
Paroxetine—HTR2A—endothelium—melanoma	0.000263	0.0412	CbGeAlD
Paroxetine—Hypersensitivity—Carmustine—melanoma	0.000262	0.000646	CcSEcCtD
Paroxetine—Diarrhoea—Dactinomycin—melanoma	0.00026	0.000641	CcSEcCtD
Paroxetine—Vomiting—Bleomycin—melanoma	0.000259	0.000639	CcSEcCtD
Paroxetine—Anaemia—Docetaxel—melanoma	0.000258	0.000638	CcSEcCtD
Paroxetine—Rash—Bleomycin—melanoma	0.000256	0.000634	CcSEcCtD
Paroxetine—Dermatitis—Bleomycin—melanoma	0.000256	0.000633	CcSEcCtD
Paroxetine—Asthenia—Carmustine—melanoma	0.000255	0.000629	CcSEcCtD
Paroxetine—Hypersensitivity—Temozolomide—melanoma	0.000253	0.000624	CcSEcCtD
Paroxetine—Syncope—Docetaxel—melanoma	0.000251	0.000619	CcSEcCtD
Paroxetine—Leukopenia—Docetaxel—melanoma	0.00025	0.000618	CcSEcCtD
Paroxetine—Palpitations—Docetaxel—melanoma	0.000247	0.00061	CcSEcCtD
Paroxetine—Asthenia—Temozolomide—melanoma	0.000246	0.000608	CcSEcCtD
Paroxetine—Loss of consciousness—Docetaxel—melanoma	0.000246	0.000607	CcSEcCtD
Paroxetine—Cough—Docetaxel—melanoma	0.000244	0.000603	CcSEcCtD
Paroxetine—Diarrhoea—Carmustine—melanoma	0.000243	0.0006	CcSEcCtD
Paroxetine—HTR2A—blood vessel—melanoma	0.000243	0.038	CbGeAlD
Paroxetine—Pruritus—Temozolomide—melanoma	0.000243	0.0006	CcSEcCtD
Paroxetine—Convulsion—Docetaxel—melanoma	0.000242	0.000598	CcSEcCtD
Paroxetine—Nausea—Bleomycin—melanoma	0.000242	0.000597	CcSEcCtD
Paroxetine—Hypertension—Docetaxel—melanoma	0.000241	0.000596	CcSEcCtD
Paroxetine—Vomiting—Dactinomycin—melanoma	0.000241	0.000596	CcSEcCtD
Paroxetine—Rash—Dactinomycin—melanoma	0.000239	0.000591	CcSEcCtD
Paroxetine—Chest pain—Docetaxel—melanoma	0.000238	0.000588	CcSEcCtD
Paroxetine—Arthralgia—Docetaxel—melanoma	0.000238	0.000588	CcSEcCtD
Paroxetine—Myalgia—Docetaxel—melanoma	0.000238	0.000588	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000236	0.000584	CcSEcCtD
Paroxetine—Dizziness—Carmustine—melanoma	0.000235	0.00058	CcSEcCtD
Paroxetine—Diarrhoea—Temozolomide—melanoma	0.000235	0.00058	CcSEcCtD
Paroxetine—Dry mouth—Docetaxel—melanoma	0.000233	0.000575	CcSEcCtD
Paroxetine—Confusional state—Docetaxel—melanoma	0.00023	0.000568	CcSEcCtD
Paroxetine—Oedema—Docetaxel—melanoma	0.000228	0.000564	CcSEcCtD
Paroxetine—Anaphylactic shock—Docetaxel—melanoma	0.000228	0.000564	CcSEcCtD
Paroxetine—Dizziness—Temozolomide—melanoma	0.000227	0.00056	CcSEcCtD
Paroxetine—Infection—Docetaxel—melanoma	0.000227	0.00056	CcSEcCtD
Paroxetine—Vomiting—Carmustine—melanoma	0.000226	0.000558	CcSEcCtD
Paroxetine—Nausea—Dactinomycin—melanoma	0.000225	0.000557	CcSEcCtD
Paroxetine—Shock—Docetaxel—melanoma	0.000225	0.000555	CcSEcCtD
Paroxetine—Rash—Carmustine—melanoma	0.000224	0.000553	CcSEcCtD
Paroxetine—Nervous system disorder—Docetaxel—melanoma	0.000224	0.000553	CcSEcCtD
Paroxetine—Dermatitis—Carmustine—melanoma	0.000224	0.000552	CcSEcCtD
Paroxetine—Thrombocytopenia—Docetaxel—melanoma	0.000223	0.000552	CcSEcCtD
Paroxetine—Tachycardia—Docetaxel—melanoma	0.000223	0.00055	CcSEcCtD
Paroxetine—Headache—Carmustine—melanoma	0.000222	0.000549	CcSEcCtD
Paroxetine—Skin disorder—Docetaxel—melanoma	0.000222	0.000547	CcSEcCtD
Paroxetine—CHRM5—head—melanoma	0.000221	0.0346	CbGeAlD
Paroxetine—Vomiting—Temozolomide—melanoma	0.000218	0.000539	CcSEcCtD
Paroxetine—Rash—Temozolomide—melanoma	0.000216	0.000534	CcSEcCtD
Paroxetine—Dermatitis—Temozolomide—melanoma	0.000216	0.000534	CcSEcCtD
Paroxetine—Headache—Temozolomide—melanoma	0.000215	0.000531	CcSEcCtD
Paroxetine—Hypotension—Docetaxel—melanoma	0.000213	0.000527	CcSEcCtD
Paroxetine—Nausea—Carmustine—melanoma	0.000211	0.000521	CcSEcCtD
Paroxetine—TACR1—lymph node—melanoma	0.000211	0.033	CbGeAlD
Paroxetine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000208	0.000514	CcSEcCtD
Paroxetine—Insomnia—Docetaxel—melanoma	0.000206	0.00051	CcSEcCtD
Paroxetine—Paraesthesia—Docetaxel—melanoma	0.000205	0.000506	CcSEcCtD
Paroxetine—Nausea—Temozolomide—melanoma	0.000204	0.000503	CcSEcCtD
Paroxetine—Dyspnoea—Docetaxel—melanoma	0.000203	0.000503	CcSEcCtD
Paroxetine—Somnolence—Docetaxel—melanoma	0.000203	0.000501	CcSEcCtD
Paroxetine—Dyspepsia—Docetaxel—melanoma	0.000201	0.000496	CcSEcCtD
Paroxetine—Decreased appetite—Docetaxel—melanoma	0.000198	0.00049	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Docetaxel—melanoma	0.000197	0.000487	CcSEcCtD
Paroxetine—Fatigue—Docetaxel—melanoma	0.000197	0.000486	CcSEcCtD
Paroxetine—Constipation—Docetaxel—melanoma	0.000195	0.000482	CcSEcCtD
Paroxetine—Pain—Docetaxel—melanoma	0.000195	0.000482	CcSEcCtD
Paroxetine—Feeling abnormal—Docetaxel—melanoma	0.000188	0.000464	CcSEcCtD
Paroxetine—Gastrointestinal pain—Docetaxel—melanoma	0.000187	0.000461	CcSEcCtD
Paroxetine—Abdominal pain—Docetaxel—melanoma	0.00018	0.000446	CcSEcCtD
Paroxetine—Body temperature increased—Docetaxel—melanoma	0.00018	0.000446	CcSEcCtD
Paroxetine—HTR2A—neck—melanoma	0.000174	0.0272	CbGeAlD
Paroxetine—Hypersensitivity—Docetaxel—melanoma	0.000168	0.000415	CcSEcCtD
Paroxetine—Asthenia—Docetaxel—melanoma	0.000164	0.000404	CcSEcCtD
Paroxetine—Pruritus—Docetaxel—melanoma	0.000161	0.000399	CcSEcCtD
Paroxetine—ABCB1—blood vessel—melanoma	0.000159	0.0249	CbGeAlD
Paroxetine—Diarrhoea—Docetaxel—melanoma	0.000156	0.000386	CcSEcCtD
Paroxetine—CHRM2—head—melanoma	0.000152	0.0237	CbGeAlD
Paroxetine—SLC6A3—head—melanoma	0.000151	0.0237	CbGeAlD
Paroxetine—Dizziness—Docetaxel—melanoma	0.000151	0.000373	CcSEcCtD
Paroxetine—Vomiting—Docetaxel—melanoma	0.000145	0.000358	CcSEcCtD
Paroxetine—Rash—Docetaxel—melanoma	0.000144	0.000355	CcSEcCtD
Paroxetine—Dermatitis—Docetaxel—melanoma	0.000144	0.000355	CcSEcCtD
Paroxetine—Headache—Docetaxel—melanoma	0.000143	0.000353	CcSEcCtD
Paroxetine—SLC6A4—head—melanoma	0.000139	0.0217	CbGeAlD
Paroxetine—CHRM1—head—melanoma	0.000138	0.0216	CbGeAlD
Paroxetine—CYP2B6—skin of body—melanoma	0.000138	0.0216	CbGeAlD
Paroxetine—Nausea—Docetaxel—melanoma	0.000136	0.000335	CcSEcCtD
Paroxetine—HTR2A—eye—melanoma	0.000129	0.0202	CbGeAlD
Paroxetine—HTR2A—retina—melanoma	0.000128	0.02	CbGeAlD
Paroxetine—CHRM3—head—melanoma	0.000124	0.0193	CbGeAlD
Paroxetine—SLC6A2—head—melanoma	0.000122	0.0191	CbGeAlD
Paroxetine—CYP2B6—head—melanoma	8.99e-05	0.0141	CbGeAlD
Paroxetine—SLC6A2—lymph node—melanoma	8.55e-05	0.0134	CbGeAlD
Paroxetine—ABCB1—retina—melanoma	8.39e-05	0.0131	CbGeAlD
Paroxetine—HTR2A—head—melanoma	7.34e-05	0.0115	CbGeAlD
Paroxetine—ABCB1—mammalian vulva—melanoma	6.72e-05	0.0105	CbGeAlD
Paroxetine—CYP2D6—head—melanoma	6.68e-05	0.0105	CbGeAlD
Paroxetine—ABCB1—head—melanoma	4.81e-05	0.00752	CbGeAlD
Paroxetine—ABCB1—lymph node—melanoma	3.37e-05	0.00527	CbGeAlD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—melanoma	1.08e-05	3.97e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ERCC2—melanoma	1.08e-05	3.97e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK3—melanoma	1.08e-05	3.97e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK3—melanoma	1.08e-05	3.95e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—melanoma	1.07e-05	3.92e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK3—melanoma	1.07e-05	3.92e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—melanoma	1.07e-05	3.91e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1A—melanoma	1.06e-05	3.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—melanoma	1.06e-05	3.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—melanoma	1.06e-05	3.89e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—melanoma	1.06e-05	3.88e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NFKB1—melanoma	1.06e-05	3.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—melanoma	1.05e-05	3.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—melanoma	1.04e-05	3.81e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—melanoma	1.04e-05	3.8e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK1—melanoma	1.03e-05	3.79e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—melanoma	1.03e-05	3.79e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—melanoma	1.03e-05	3.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CB—melanoma	1.03e-05	3.78e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—melanoma	1.03e-05	3.78e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK1—melanoma	1.03e-05	3.77e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—melanoma	1.03e-05	3.77e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.03e-05	3.77e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PRKCA—melanoma	1.03e-05	3.77e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK1—melanoma	1.03e-05	3.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—melanoma	1.03e-05	3.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—melanoma	1.02e-05	3.75e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—melanoma	1.02e-05	3.74e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ERCC2—melanoma	1.02e-05	3.74e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PRKCA—melanoma	1.02e-05	3.74e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CD—melanoma	1.02e-05	3.73e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK1—melanoma	1.02e-05	3.73e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—melanoma	1.02e-05	3.73e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ERCC2—melanoma	1.01e-05	3.71e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—melanoma	1.01e-05	3.69e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAP2K1—melanoma	1e-05	3.69e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—melanoma	1e-05	3.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAP2K1—melanoma	9.99e-06	3.67e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CD—melanoma	9.98e-06	3.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAP2K1—melanoma	9.96e-06	3.65e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CD—melanoma	9.93e-06	3.64e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—melanoma	9.92e-06	3.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CD—melanoma	9.9e-06	3.63e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—melanoma	9.89e-06	3.63e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	9.89e-06	3.63e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAP2K1—melanoma	9.87e-06	3.62e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	9.83e-06	3.61e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—melanoma	9.81e-06	3.6e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—melanoma	9.8e-06	3.6e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CD—melanoma	9.8e-06	3.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—melanoma	9.77e-06	3.58e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—melanoma	9.72e-06	3.57e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—melanoma	9.71e-06	3.56e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—melanoma	9.69e-06	3.55e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—melanoma	9.59e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—melanoma	9.59e-06	3.52e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGF2—melanoma	9.56e-06	3.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGF2—melanoma	9.51e-06	3.49e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—melanoma	9.5e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK3—melanoma	9.48e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGF2—melanoma	9.48e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—melanoma	9.47e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—melanoma	9.46e-06	3.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGF2—melanoma	9.38e-06	3.44e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—melanoma	9.22e-06	3.38e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK3—melanoma	9.07e-06	3.33e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK1—melanoma	9.02e-06	3.31e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—melanoma	9.01e-06	3.31e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—melanoma	8.98e-06	3.29e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MDM2—melanoma	8.94e-06	3.28e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—melanoma	8.93e-06	3.28e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—melanoma	8.91e-06	3.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—melanoma	8.9e-06	3.26e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MDM2—melanoma	8.89e-06	3.26e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CB—melanoma	8.87e-06	3.26e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MDM2—melanoma	8.87e-06	3.25e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—melanoma	8.83e-06	3.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—melanoma	8.82e-06	3.23e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—melanoma	8.81e-06	3.23e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—melanoma	8.79e-06	3.23e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MDM2—melanoma	8.78e-06	3.22e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—melanoma	8.77e-06	3.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—melanoma	8.74e-06	3.21e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CB—melanoma	8.7e-06	3.19e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—melanoma	8.66e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CB—melanoma	8.65e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK1—melanoma	8.63e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—melanoma	8.63e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CB—melanoma	8.63e-06	3.16e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CD—melanoma	8.62e-06	3.16e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—melanoma	8.54e-06	3.13e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CB—melanoma	8.54e-06	3.13e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—melanoma	8.52e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—melanoma	8.51e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.37e-06	3.07e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—melanoma	8.36e-06	3.07e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—melanoma	8.32e-06	3.05e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—melanoma	8.31e-06	3.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—melanoma	8.29e-06	3.04e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—melanoma	8.26e-06	3.03e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—melanoma	8.24e-06	3.02e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—melanoma	8.24e-06	3.02e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—melanoma	8.21e-06	3.01e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1B—melanoma	8.16e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—melanoma	8.16e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—melanoma	8.15e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1B—melanoma	8.12e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1B—melanoma	8.09e-06	2.97e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—melanoma	8.08e-06	2.96e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—melanoma	8.05e-06	2.95e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—melanoma	8.03e-06	2.95e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1B—melanoma	8.02e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—melanoma	8.01e-06	2.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—melanoma	8e-06	2.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—melanoma	7.99e-06	2.93e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—melanoma	7.98e-06	2.93e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—melanoma	7.96e-06	2.92e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—melanoma	7.95e-06	2.92e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—melanoma	7.95e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—melanoma	7.93e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—melanoma	7.93e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—melanoma	7.92e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—melanoma	7.91e-06	2.9e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—melanoma	7.88e-06	2.89e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—melanoma	7.86e-06	2.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—melanoma	7.84e-06	2.88e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—melanoma	7.82e-06	2.87e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—melanoma	7.81e-06	2.86e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—melanoma	7.79e-06	2.86e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—melanoma	7.77e-06	2.85e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—melanoma	7.75e-06	2.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—melanoma	7.72e-06	2.83e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CTNNB1—melanoma	7.71e-06	2.83e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—melanoma	7.7e-06	2.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CTNNB1—melanoma	7.67e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—melanoma	7.67e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—melanoma	7.65e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CTNNB1—melanoma	7.65e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CTNNB1—melanoma	7.57e-06	2.78e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—melanoma	7.57e-06	2.78e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—melanoma	7.56e-06	2.77e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1A—melanoma	7.53e-06	2.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—melanoma	7.52e-06	2.76e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—melanoma	7.52e-06	2.76e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CB—melanoma	7.51e-06	2.76e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CD—melanoma	7.51e-06	2.75e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—melanoma	7.5e-06	2.75e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1A—melanoma	7.49e-06	2.75e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—melanoma	7.49e-06	2.75e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKB1—melanoma	7.48e-06	2.74e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—melanoma	7.48e-06	2.74e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1A—melanoma	7.47e-06	2.74e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—melanoma	7.45e-06	2.73e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—melanoma	7.44e-06	2.73e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKB1—melanoma	7.44e-06	2.73e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—melanoma	7.42e-06	2.72e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKB1—melanoma	7.42e-06	2.72e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—melanoma	7.41e-06	2.72e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1A—melanoma	7.4e-06	2.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—melanoma	7.38e-06	2.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKB1—melanoma	7.35e-06	2.69e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—melanoma	7.33e-06	2.69e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—melanoma	7.29e-06	2.68e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—melanoma	7.27e-06	2.67e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—melanoma	7.25e-06	2.66e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—melanoma	7.24e-06	2.65e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—melanoma	7.2e-06	2.64e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CD—melanoma	7.08e-06	2.6e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CD—melanoma	7.02e-06	2.57e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—melanoma	6.99e-06	2.56e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—melanoma	6.93e-06	2.54e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—melanoma	6.93e-06	2.54e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—melanoma	6.93e-06	2.54e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—melanoma	6.79e-06	2.49e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—melanoma	6.75e-06	2.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—melanoma	6.73e-06	2.47e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—melanoma	6.72e-06	2.47e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—melanoma	6.71e-06	2.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—melanoma	6.69e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—melanoma	6.67e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—melanoma	6.67e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—melanoma	6.67e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—melanoma	6.65e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—melanoma	6.63e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—melanoma	6.6e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—melanoma	6.59e-06	2.42e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CB—melanoma	6.55e-06	2.4e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—melanoma	6.49e-06	2.38e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—melanoma	6.49e-06	2.38e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK3—melanoma	6.42e-06	2.36e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—melanoma	6.39e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK3—melanoma	6.39e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK3—melanoma	6.37e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK3—melanoma	6.31e-06	2.31e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—melanoma	6.29e-06	2.31e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—melanoma	6.25e-06	2.29e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—melanoma	6.21e-06	2.28e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—melanoma	6.19e-06	2.27e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CB—melanoma	6.17e-06	2.26e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—melanoma	6.13e-06	2.25e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—melanoma	6.12e-06	2.24e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CB—melanoma	6.11e-06	2.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK1—melanoma	6.11e-06	2.24e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—melanoma	6.11e-06	2.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—melanoma	6.11e-06	2.24e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK1—melanoma	6.08e-06	2.23e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—melanoma	6.08e-06	2.23e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK1—melanoma	6.06e-06	2.22e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—melanoma	6.06e-06	2.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—melanoma	6.06e-06	2.22e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK1—melanoma	6e-06	2.2e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—melanoma	6e-06	2.2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—melanoma	5.77e-06	2.12e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—melanoma	5.74e-06	2.11e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—melanoma	5.72e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—melanoma	5.67e-06	2.08e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—melanoma	5.66e-06	2.07e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—melanoma	5.41e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—melanoma	5.33e-06	1.95e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—melanoma	5.3e-06	1.95e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—melanoma	5.28e-06	1.94e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—melanoma	5.28e-06	1.93e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—melanoma	5.26e-06	1.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—melanoma	5.21e-06	1.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—melanoma	5.14e-06	1.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—melanoma	5.13e-06	1.88e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—melanoma	5.1e-06	1.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—melanoma	5.09e-06	1.87e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—melanoma	5.04e-06	1.85e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—melanoma	4.91e-06	1.8e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—melanoma	4.88e-06	1.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—melanoma	4.86e-06	1.78e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—melanoma	4.82e-06	1.77e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—melanoma	4.7e-06	1.72e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—melanoma	4.67e-06	1.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—melanoma	4.66e-06	1.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—melanoma	4.61e-06	1.69e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—melanoma	4.58e-06	1.68e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—melanoma	4.42e-06	1.62e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—melanoma	4.33e-06	1.59e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—melanoma	4.31e-06	1.58e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—melanoma	4.3e-06	1.58e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—melanoma	4.25e-06	1.56e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—melanoma	3.99e-06	1.46e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—melanoma	3.76e-06	1.38e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—melanoma	3.74e-06	1.37e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—melanoma	3.73e-06	1.37e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—melanoma	3.26e-06	1.2e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—melanoma	3.07e-06	1.13e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—melanoma	3.05e-06	1.12e-05	CbGpPWpGaD
